• Novartis reported Phase III RemIND results showing Rhapsido (remibrutinib) sustained symptom relief through 52 weeks across three chronic inducible urticaria subtypes.
• Patients switching from placebo achieved similar long-term responses; safety remained consistent with previous studies.
• The findings will support additional regulatory submissions for chronic inducible urticaria.
• Results will be presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novartis AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611121157OMX_____CNEWS_EN_GNW1001303359_en) on November 12, 2026, and is solely responsible for the information contained therein.